NOVEL EGFR/PI3K DUAL-TARGETING NANOPARTICLES INDUCE IMMUNOGENIC CELL DEATH IN BLADDER CANCER

被引：0
|
作者：
Zhu, Zheng [1 ]
Xue, Xiangdong [2 ]
Zhou, Gang [3 ]
Song, Zewen [4 ]
Li, Guoyin [5 ]
机构：
[1] Harvard Med Sch, West Roxbury, MA USA
[2] Shanghai Jiao Tong Univ, Shanghai, Peoples R China
[3] Fourth Millitary Med Univ, Xian, Peoples R China
[4] Cent South Univ, Changsha, Peoples R China
[5] Zhoukou Normal Univ, Zhoukou, Henan, Peoples R China
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2022年 / 10卷
关键词：
D O I：
10.1136/jitc-2022-SITC2022.1358
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1358
引用
收藏
页码：A1409 / A1409
页数：1
相关论文
共 50 条
  • [21] The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer
    Shimizu, Toshio
    Tolcher, Anthony W.
    Papadopoulos, Kyriakos P.
    Beeram, Muralidhar
    Rasco, Drew W.
    Smith, Lon S.
    Gunn, Shelly
    Smetzer, Leslie
    Mays, Theresa A.
    Kaiser, Brianne
    Wick, Michael J.
    Alvarez, Cathy
    Cavazos, Aracely
    Mangold, Gina L.
    Patnaik, Amita
    CLINICAL CANCER RESEARCH, 2012, 18 (08) : 2316 - 2325
  • [22] Lysoglycosphingolipids have the ability to induce cell death through direct PI3K inhibition
    Watanabe, Ryosuke
    Tsuji, Daisuke
    Tanaka, Hiroki
    Uno, Michael Shintaro
    Ohnishi, Yukiya
    Kitaguchi, Shindai
    Matsugu, Tsuyoshi
    Nakae, Ryuto
    Teramoto, Hiromi
    Yamamoto, Kei
    Shinohara, Yasuo
    Hirokawa, Takatsugu
    Okino, Nozomu
    Ito, Makoto
    Itoh, Kohji
    JOURNAL OF NEUROCHEMISTRY, 2023, 167 (06) : 753 - 765
  • [23] The PI3K inhibitor copanlisib synergizes with sorafenib to induce cell death in hepatocellular carcinoma
    Liangtao Ye
    Julia Mayerle
    Andreas Ziesch
    Florian P. Reiter
    Alexander L. Gerbes
    Enrico N. De Toni
    Cell Death Discovery, 5
  • [24] The PI3K inhibitor copanlisib synergizes with sorafenib to induce cell death in hepatocellular carcinoma
    Ye, Liangtao
    Mayerle, Julia
    Ziesch, Andreas
    Reiter, Florian P.
    Gerbes, Alexander L.
    De Toni, Enrico N.
    CELL DEATH DISCOVERY, 2019, 5 (1)
  • [25] Targeting the PI3K/Akt Cell Survival Pathway to Induce Cell Death of HIV-1 Infected Macrophages with Alkylphospholipid Compounds
    Lucas, Amanda
    Kim, Yuri
    Rivera-Pabon, Omayra
    Chae, Sunju
    Kim, Dong-Hyun
    Kim, Baek
    PLOS ONE, 2010, 5 (09): : 1 - 8
  • [26] Targeting EGFR/PI3K/AKT/mTOR Signaling in Hepatocellular Carcinoma
    Bang, Jieun
    Jun, Mihyeon
    Lee, Soyun
    Moon, Hyuk
    Ro, Simon Weonsang
    PHARMACEUTICS, 2023, 15 (08)
  • [27] Saikosaponin-A Exhibits Antipancreatic Cancer Activity by Targeting the EGFR/PI3K/Akt Pathway
    Shi, Chengda
    Sun, Linglin
    Fang, Rong
    Zheng, Shuying
    Yu, Mingming
    Li, Qiang
    CURRENT PHARMACEUTICAL BIOTECHNOLOGY, 2023, 24 (04) : 579 - 588
  • [28] Co-encapsulated nanoparticles of Erlotinib and Quercetin for targeting lung cancer through nuclear EGFR and PI3K/AKT inhibition
    Ganthala, Parimala Devi
    Alavala, Sateesh
    Chella, Naveen
    Andugulapati, Sai Balaji
    Bathini, Nagendra Babu
    Sistla, Ramakrishna
    COLLOIDS AND SURFACES B-BIOINTERFACES, 2022, 211
  • [29] Targeting PI3K and RAS pathways in a novel preclinical model of prostate cancer
    Pearson, Helen B.
    Humbert, Patrick O.
    Phillips, Wayne A.
    MOLECULAR CANCER THERAPEUTICS, 2015, 14 (07)
  • [30] Analysis of PI3K pathway genes in bladder cancer
    Seven, Didem
    Tigli, Hatice
    Buyru, Nur
    CANCER RESEARCH, 2012, 72
12345